Pfizer and BioNTech steam ahead with up to date Comirnaty jab

14 October 2022

New data from Pfizer (NYSE: PFE) and BioNTech’s (Nasdaq: BNTX) Comirnaty program show the firms’ updated jab produces antibodies against the latest variants of the coronavirus.

Early data from a Phase II/III trial show the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine generated a substantial increase in neutralizing antibody responses, seven days after administration.

The firms said that similar responses were seen across individuals aged 18 to 55 years of age and those older than 55 years of age.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK